The diagnosis of invasive fungal infections from radiographic imaging is non-specifi c and problematic. As a fi rst step toward increasing specifi city, we describe the development of a broad-spectrum fungal-specifi c targeting molecule, which when modifi ed with a fl uorescent label fully retains its targeting properties, and provides a basis for future imaging applications.
Imaging is an important part of the diagnosis of diseases, such as invasive aspergillosis (IA). Characteristic images from conventional X-rays and more advanced computed tomography (CT) can be used to identify disease lesions in neutropenic patients and help manage IA. Importantly, the CT halo sign is a transient fi nding that provides a probable diagnosis of early invasive pulmonary aspergillosis. Patients with a halo sign at baseline are more likely to have a satisfactory treatment response than those without this indicator [11] . Unfortunately, diagnostic imaging is inherently non-specifi c and must be used in combination with other clinical and microbiological factors. An important adjunct for imaging would be the development of fungal-specifi c probes that can be used to specifi cally image infecting pathogens in the lungs of patients. In this report, we describe the development of novel fungalspecifi c probes that have the potential to be used for diagnostic imaging.
Our approach takes advantage of highly specifi c and sensitive antifungal drugs with known safety properties as targeting molecules. By coupling a fl uorophore that can be visualized, the new probe would be able to detect the presence of fungal pathogens. The echinocandin drug caspofungin (CSF) binds with high affi nity to its fungal target glucan synthase [12, 13] , which is not found in humans. This fungal specifi city potentially makes it a powerful and highly discriminating diagnostic tool for the sensitive detection and visualization of fungal pathogens, when
Introduction
Invasive fungal infections (IFI) are a growing threat to human health due to immunocompromising diseases [1] . In most situations where IFI diagnosis is considered, the clinical presentation is often non-specifi c and can be caused by a wide range of infectious organisms, underlying illness, or complications of treatment. Successful IFI diagnosis is further complicated due to uncertainties and controversies in disease defi nition and in selecting standardized methods for establishing the diagnosis [1, 2] . Fungal cell wall components such as glucans and galactomannans, which are actively shed during growth and development, are the basis for biomarker-based commercial antigen assays for rapid diagnostic testing [3] , but their value is limited by the potential for false-positive and false-negative results due to an assortment of factors [4 -8] .
In recent years, standardization of protocols for PCR amplifi cation of organisms, such as Aspergillus spp. from blood and respiratory samples [9] has aided in the diagnosis of these infections, especially since cultures are often negative [10] .
coupled with a suitable label [4] . The antifungal molecule caspofungin (CSF) shows broad activity against clinically important Candida and Aspergillus spp. [12] . It contains two aliphatic primary amino groups that are convenient sites for chemical modifi cation, which facilitate the engineering of broad-spectrum labeled probes.
Methods and materials

Synthesis of BODIPY-labeled drugs
A derivative of CSF using BODIPY (BOD) (Fig. 1) was produced by incubating BODIPY-succinimidate with pure CSF in the presence of triethylamine as a proton acceptor in DMF. The crude product was purifi ed by TLC silica gel chromatography and characterized using mass spectroscopy, fl uorescence and UV spectroscopy (not shown). It was critical that the modifi ed agent retained its specifi city and sensitivity to the fungal target. To test these properties, the antifungal activity of the modifi ed and unmodifi ed root compounds were evaluated and found to be effectively unaltered by the presence of label ( C. albicans MIC unlabeled ϭ 0.06 μ g/ml v. MIC labeled ϭ 0.12 μ g/ml) confi rming that it retained its inherent potency. BODIPY coupled to posaconazole (POS) was formed by modifying a single hydroxyl group of posaconazole with succinic anhydride (Fig. 2) .
Incubation of the acylation product with 4-nitrophenol in the presence of N,N ′ -Dicyclohexylcarbodiimide (DCC) yielded a new compound consistent with the formation of an activated ester (compound II ). Incubation of this compound with ethylenediamine resulted in a characteristic absorption at 405 nm of nitrophenolate anion, which was indicative for acylation of the diamine by posaconazole activated ester. Incubation of the ester with aminobutane derivative of BODIPY fl uorophore (compound III ) yielded fl uorescent posaconazole-BODIPY adduct IV , with expected light absorption spectrum.
Cell labeling
To illustrate the potential of CSF-BOD and POS-BOD for visualizing fungal cells, the reagent was used to probe for the presence of Candida and Aspergillus species in a variety of matrices including solid and liquid growth media. The clinical A. fumigatus wild type strain R21 and Candida albicans ATCC strain 90028 were used for all the experiments. For Aspergillus , one drop of yeast extract peptone dextrose (YPD) agar was placed in the upper right corner of each well of a 15-well multi-test slide followed by the addition of 10 μ l of saline containing 10 5 conidia of R21. The slide was placed in a sterile Petri dish with distilled water to provide a moist environment and incubated in a 37 ° C incubator for 10 -16 h to facilitate germination and growth of hyphal elements. A 10 μ l aliquot of CSF-BOD (170 ng/ml) or POS-BOD (150 ng/ml)was added to each well and incubated for 6 h at 37 ° C, followed by washing three times with sterile water and drying by vacuum. For Candida , an overnight culture of C. albicans was grown, washed by centrifugation and resuspended in dH 2 O. The yeast cells were added to RPMI and incubated at 200 rpm for 1 h at 37 ° C to form germ tubes before being washed and resuspended in a 1 ml solution of CSF-BOD (120 ng/ ml) or POS-BOD (150 ng/ml). The cells with drug were incubated again at 200 rpm for 1 h at 37 ° C, washed and resuspended in 50 μ l of dH 2 O. A 15-well slide was prepared using a poly-L-lysine to tightly adhere cells to the wells. A 10 μ l aliquot of Candida cells was placed on each well and incubated for 10 min, aspirated off, and 1 μ l Slow Fade Antifade reagent was added to prolong the fl uorescent analyzed, and captured in bright fi eld lighting and repeated under a Green Fluorescent Protein (GFP) light setting.
Results
Incubation of C. albicans at the MIC (120 ng/ml) for 1 h at 37 ° C resulted in generalized fl uorescence in the mother life and moisture level of the cells on the each slide. Each slide was observed under 100 ϫ magnifi cation with the total internal refl ection objective lens (TIRF) of a Nikon Eclipse 90i fl uorescent microscope. All 15 wells of the slides were examined individually using Volocity ® 3D Image Analysis Software (PerkinElmer). Individual cells, hyphal elements and clusters of cells were visualized, cell membrane with slightly more defi ned punctate fl uorescence along the germ tube axis toward the growing tip, consistent with the putative intracellular vesicle traffi cking of glucan synthase from clustered golgi vesicle complexes (Fig. 3A) . Under 6 h and 37 ° C conditions, A. fumigatus showed bright fl uorescence in the spore but more diffuse labeling of the surface of the hyphal elements toward the growing apex (Fig. 3B ) consistent with a membrane location for glucan synthase. As expected, labeling was highly temperature sensitive with maximal labeling observed over the 6 h period at 37 ° C. Caspofungin and BODIPY alone failed to produce any labeling (results not shown). The level of binding was greatly reduced in a well-characterized fks 1-S645F mutant [14] , which has diminished sensitivity of glucan synthase for echinocandins consistent with the probe binding to its intended target (Fig. 3C) .
To ensure the specifi city of this method for fungi, representative Gram negative and Gram positive bacteria: Pseudomonas aeruginosa , Klebsiella pneumoniae , Streptococcus pneumoniae , Serratia marcescens , Staphylococcus aureus and Escherichia coli were grown and labeled under the same conditions. No fl uorescence was observed in any cells (results not shown).
To further confi rm the targeting properties of CSF-BOD, posaconazole, a potent and selective inhibitor of the sterol biosynthetic enzyme cytochrome p 450 lanosterol 14 α demethylase, was modifi ed with BODIPY (POS-BOD). Under the same labeling conditionsas CSF-BOD, POS-BOD showed generalized fl uorescence labeling of mother cell and elongating hyphal elements with both Candida and Aspergillus . Pretreatment with unlabeled posaconazole or voriconazole greatly diminished or eliminated the fl uorescence signal, while pretreatment with caspofungin had 
